Company intelligence / Profile preview

Xinvento

Amsterdam, Noord-Holland, Netherlands

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Xinvento developed investigational therapies for congenital hyperinsulinism; acquired before any human clinical data was reported. The lead candidate had not entered the clinic as of the Rhythm Pharmaceuticals acquisition with preclinical milestones outlined. Rhythm anticipates clinical entry in 2024.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Xinvento.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinvento.

Explore the full profile